Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c) Santaballa, A. et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/124001

SEOM Clinical Guidelines For Endometrial Cancer (2017)

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.

Citació

Citació

SANTABALLA BERTRÁN, Ana, MATIAS-GUIU, Xavier, REDONDO, A., CARBALLO, N., GIL, M., GÓMEZ, C., GOROSTIDI, M., GUTIERREZ, M., GÓNZALEZ MARTIN, A.. SEOM Clinical Guidelines For Endometrial Cancer (2017). _Clinical & Translational Oncology_. 2018. Vol. 20, núm. Issue 1, pàgs. 29-37. [consulta: 9 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/124001]

Exportar metadades

JSON - METS

Compartir registre